A combination of p53-activating APR-246 and phosphatidylserine-targeting antibody potently inhibits tumor development in hormone-dependent mutant p53-expressing breast cancer xenografts

References

• DeSantisCMaJBryanLJemalABreast cancer statistics, 2013CA Cancer J Clin201464526224114568
   PubMed Web of Science ®Google Scholar
• GarritanoSIngaAGemignaniFLandiSMore targets, more pathways and more clues for mutant p53Oncogenesis20132e5423817466
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas NetworkComprehensive molecular portraits of human breast tumoursNature2012490617023000897
   PubMed Web of Science ®Google Scholar
• TurnerNMorettiESiclariOTargeting triple negative breast cancer: is p53 the answer?Cancer Treat Rev20133954155023321033
   PubMed Web of Science ®Google Scholar
• ShapiraILeeAVoraRBudmanDRp53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potencyCrit Rev Oncol Hematol20138828429223755891
   PubMed Web of Science ®Google Scholar
• BassettEAWangWRastinejadFEl-DeiryWSStructural and functional basis for therapeutic modulation of p53 signalingClin Cancer Res2008146376638618927276
   PubMed Web of Science ®Google Scholar
• LacroixMToillonRALeclercqGp53 and breast cancer, an updateEndocr Relat Cancer20061329332516728565
   PubMed Web of Science ®Google Scholar
• KumarSWaliaVRayMElbleRCp53 in breast cancer: mutation and counter measuresFront Biosci2007124168417817485365
   PubMed Web of Science ®Google Scholar
• RahkoEBlancoGSoiniYBloiguRJukkolaAA mutant TP53 gene status is associated with a poor prognosis and anthracycline- resistance in breast cancer patientsEur J Cancer20033944745312751374
   PubMed Web of Science ®Google Scholar
• MullerMWilderSBannaschDp53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugsJ Exp Med1998188203320459841917
   PubMed Web of Science ®Google Scholar
• WangWRastinejadFEL-DeiryWSRestoring p53-dependent tumor suppressionCancer Biol Ther20032S55S6314508081
   PubMed Web of Science ®Google Scholar
• StoklosaTGolabJProspects for p53-based cancer therapyActa Biochimica Polonica20055232132815990917
   PubMed Web of Science ®Google Scholar
• WillisACChenXThe promise and obstacle of p53 as a cancer therapeutic agentCurr Mol Med2002232934512108946
   PubMedGoogle Scholar
• FosterBACoffeyHAMorinMJRastinejadFPharmacological rescue of mutant p53 conformation and functionScience19992862507251010617466
   PubMed Web of Science ®Google Scholar
• BykovVJIssaevaNShilovARestoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compoundNat Med2002828288811875500
   PubMed Web of Science ®Google Scholar
• LiangYWuJStancelGMHyderSMp53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cellsJ Steroid Biochem Mol Biol20059317318215860260
   PubMed Web of Science ®Google Scholar
• LiangYBesch-WillifordCBenakanakereIHyderSMRe-activation of the p53 pathway inhibits in vivo and in vitro growth of hormone-dependent human breast cancer cellsInt J Oncol20073177778417786308
   PubMed Web of Science ®Google Scholar
• LiangYBesch-WillifordCHyderSMPRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 proteinInt J Oncol2009351015102319787255
   PubMed Web of Science ®Google Scholar
• BykovVJWimanKGMutant p53 reactivation by small molecules makes its way to the clinicFEBS Lett20145882622262724768524
   PubMed Web of Science ®Google Scholar
• BykovVJZhangQZhangMCederSAbrahmsenLWimanKGTargeting of mutant p53 and the cellular redox balance by APR-246 as a strategy for efficient cancer therapyFront Oncol201662126870698
   PubMed Web of Science ®Google Scholar
• DenebergSCherifHLazarevicVAn open-label phase I dose- finding study of APR-246 in hematological malignanciesBlood Cancer J20166e44727421096
   PubMed Web of Science ®Google Scholar
• FolkmanJAngiogenesis in cancer, vascular, rheumatoid and other diseaseNat Med1995127317584949
   PubMed Web of Science ®Google Scholar
• BergersGBenjaminLETumorigenesis and the angiogenic switchNat Rev Cancer2003340141012778130
   PubMed Web of Science ®Google Scholar
• ThorpePEVascular targeting agents as cancer therapeuticsClin Cancer Res20041041542714760060
   PubMed Web of Science ®Google Scholar
• BurrowsFJThorpePEVascular targeting agents as cancer therapeuticsClin Cancer Res2004104152714760060
   PubMed Web of Science ®Google Scholar
• DenekampJAngiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapyBr J Radiol1993661811967682469
   PubMed Web of Science ®Google Scholar
• RanSDownesAThorpePIncreased exposure of anionic phospholipids on the surface of tumor blood vesselsCancer Res2002626132614012414638
   PubMed Web of Science ®Google Scholar
• RanSHeJHuangXSoaresMScothornDThorpePEAntitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in miceClin Cancer Res20051515511562
   Web of Science ®Google Scholar
• LusterTAHeJHuangXPlasma protein beta-2-glycoprotein 1 mediates interaction between the anti- tumor monoclonal antibody 3G4 and anionic phospholipids on endothelial cellsJ Biol Chem2006281298632987116905548
   PubMed Web of Science ®Google Scholar
• HuangXBennettMThorpePEA monoclonal antibody that binds anionic phospholipids on tumor blood vessels enhances the antitumor effect of docetaxel on human breast tumor in miceCancer Res2005654408441615899833
   PubMed Web of Science ®Google Scholar
• HeJLusterTAThorpePERadiation-enhanced vascular targeting of human lung cancers in mice with a monoclonal antibody that binds anionic phospholipidsClin Cancer Res2007135211521817785577
   PubMed Web of Science ®Google Scholar
• EmdeAMahlknechtGMaslakKSimultaneous inhibition of estrogen receptor and the HER2 pathway in breast cancer: effects of HER2 abundanceTransl Oncol2011429330021966546
   PubMed Web of Science ®Google Scholar
• CarrollCELiangYBenakanakereIBesch-WillifordCHyderSMThe anticancer agent YC-1 suppresses progestin-stimulated VEGF in breast cancer cells and arrests breast tumor developmentInt J Oncol20134217918723123638
   PubMed Web of Science ®Google Scholar
• AliSRasoolMChaoudhryHMolecular mechanisms and mode of tamoxifen resistance in breast cancerBioinformation20161213513928149048
   PubMed Web of Science ®Google Scholar
• RubinsteinLVShoemakerRHPaullKDComparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell linesJ Natl Cancer Inst199082111311182359137
   PubMed Web of Science ®Google Scholar
• SkehanPStorengRScudieroDNew colorimetric cytotoxicity assay for anti-cancer-drug screeningJ Natl Cancer Inst199082110711122359136
   PubMed Web of Science ®Google Scholar
• BreenECVEGF in biological controlJ Cell Biochem20071021358136717979153
   PubMed Web of Science ®Google Scholar
• LiangYBrekkenRAHyderSMVascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti- proliferative activity of anti- hormonesEndocrinology200613905919
   Google Scholar
• YinYHuangXLynnKDThorpePEPhosphatidylserine-targeting antibody induces M1 macrophage polarization and promotes myeloid-derived suppressor cell differentiationCancer Immunol Res2013125626824777853
   PubMed Web of Science ®Google Scholar
• ChengXLiLThorpePEYoppACBrekkenRAHuangXAntibody-mediated blockade of phosphatidylserine enhances the antitumor effect of sorafenib in hepatocellular carcinomas xenograftsAnn Surg Oncol201623Suppl 558359126847681
   PubMed Web of Science ®Google Scholar
• HarrisLNLiotchevaVBroadwaterGComparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapyJ Clin Oncol2001191698170611250999
   PubMed Web of Science ®Google Scholar
• Badowska-KozakiewiczAMSobolMPateraJKozłowskiWImmunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in invasive breast cancer in womenArch Med Sci2013946647123847668
   PubMed Web of Science ®Google Scholar
• SlamonDJGodolphinWJonesLAStudies of the HER-2/neu proto-oncogene in human breast and ovarian cancerScience19892447077122470152
   PubMed Web of Science ®Google Scholar
• PaikSHazanRFisherERPathologic findings from the national surgical adjuvant breast and bowel project: prognostic significance of erbB-2 protein overexpression in primary breast cancerClin Oncol19908103112
   Web of Science ®Google Scholar
• ToikkanenSHelinHIsolaJJoensuuHPrognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-yr follow-upJ Clin Oncol199210104410481351537
   PubMed Web of Science ®Google Scholar
• IsolaJHolliKOksaHTeramotoYKallioniemiOPElevated erbB2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancerCancer1994736526587905363
   PubMed Web of Science ®Google Scholar
• SavellanoMDPogueBWHoopesPJVitettaESPaulsenKDMultiepitope HER-2 targeting enhances photoimmunotherapy of HER-2-Overexpressing cancer cells with pyropheophorbide-a immunoconjugatesCancer Res2005656371637916024640
   PubMed Web of Science ®Google Scholar